---
figid: PMC7872905__LCTT-12-1-g0001
figtitle: Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors
  Through Co-Targeting MEK/ERK Signaling
organisms:
- Homo sapiens
- Mus musculus
- NA
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7872905
filename: LCTT-12-1-g0001.jpg
figlink: pmc/articles/PMC7872905/figure/f0001/
number: F1
caption: Schematic illustration of Ras/Raf/MEK/ERK signaling downstream of cell membranes
  tyrosine kinase receptors including EGFR that negatively regulate apoptosis through
  modulating degradation of Bim and Mcl-1 (A), mechanism by which osimertinib induces
  apoptosis in the sensitive EGFR-mutant NSCLC cells though targeting this pathway
  (A), and rationale for co-targeting mutant EGFR (mEGFR) and MEK/ERK to enhance apoptosis
  in the resistant EGFR-mutant NSCLC cells (B). The red arrows indicate the changes
  caused by osimertinib (A) or the combination of osimertinib with a MEK (eg, trametinib)
  or ERK (eg, GDC0994) inhibitor (B). amp, amplification; mut, mutation.
papertitle: Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase
  Inhibitors Through Co-Targeting MEK/ERK Signaling.
reftext: Danlei Yu, et al. Lung Cancer (Auckl). 2021;12:1-10.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9570814
figid_alias: PMC7872905__F1
figtype: Figure
redirect_from: /figures/PMC7872905__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7872905__LCTT-12-1-g0001.html
  '@type': Dataset
  description: Schematic illustration of Ras/Raf/MEK/ERK signaling downstream of cell
    membranes tyrosine kinase receptors including EGFR that negatively regulate apoptosis
    through modulating degradation of Bim and Mcl-1 (A), mechanism by which osimertinib
    induces apoptosis in the sensitive EGFR-mutant NSCLC cells though targeting this
    pathway (A), and rationale for co-targeting mutant EGFR (mEGFR) and MEK/ERK to
    enhance apoptosis in the resistant EGFR-mutant NSCLC cells (B). The red arrows
    indicate the changes caused by osimertinib (A) or the combination of osimertinib
    with a MEK (eg, trametinib) or ERK (eg, GDC0994) inhibitor (B). amp, amplification;
    mut, mutation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Erbb2
  - ras
  - Hras
  - Kras
  - Rem1
  - Mmut
  - Zhx2
  - Mdk
  - Ephb2
  - Mapk1
  - Bcl2l11
  - Mcl1
  - ERBB2
  - APRT
  - MFAP1
  - KRAS
  - HRAS
  - NRAS
  - MMUT
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - BCL2L11
  - MCL1
  - La
  - Amph
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Osimertinib
  - Trametinib
  - GDC0994
---
